Continuous Glucose Monitor

January AI CGM Platform

• 74/100 science score
• $288 price

Overview

High effectiveness from validated CGM accuracy (MARD 9.2%, pivotal trials) and January cohort data (n=944 TIR +10.8%, n=2217 weight loss). Safety tempered by Libre recall (860 injuries/7 deaths) and adhesive allergies, but no app-specific issues in studies. Quality strong via FDA clearance and peer-reviewed evidence, lacking supplement-style certs. Overall, innovative AI platform elevates standard CGM for non-diabetics.

Key strengths

• FDA-cleared FreeStyle Libre 2 sensor with 9.2% MARD accuracy from pivotal trials
• Peer-reviewed cohorts (n=944, npj 2025) show 10.8% TIR gain, 3.3 lb weight loss
• AI digital twin enables predictions post-14 days, reducing ongoing sensor need

Our analysis

January AI CGM Platform excels with FDA-cleared Libre sensor (9.2% MARD) and AI-driven insights validated in cohorts (n=944 TIR +10.8%). Ideal for non-diabetics seeking metabolic optimization, but monitor for skin reactions and recent Libre recalls.

Frequently asked questions

Is January AI CGM Platform worth buying?

January AI CGM Platform has a Verify Influencers trust score of 74/100 based on ingredient quality, clinical evidence, and third-party testing.

What is the trust score for January AI CGM Platform?

January AI CGM Platform scored 74 out of 100 in our science-backed analysis, which evaluates ingredient dosages against clinical literature and manufacturing transparency.

Browse all scored products · How products are scored